See more : AngloGold Ashanti Limited (AULGF) Income Statement Analysis – Financial Results
Complete financial analysis of RedHill Biopharma Ltd. (RDHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RedHill Biopharma Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Pathfinder Ventures Inc. (RV.V) Income Statement Analysis – Financial Results
- Autoneum Holding AG (ATNNF) Income Statement Analysis – Financial Results
- DTXS Silk Road Investment Holdings Company Limited (0620.HK) Income Statement Analysis – Financial Results
- Radiant Innovation Inc. (3373.TWO) Income Statement Analysis – Financial Results
- BNP Paribas SA (BNPQY) Income Statement Analysis – Financial Results
RedHill Biopharma Ltd. (RDHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.redhillbio.com
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 61.80M | 85.76M | 64.36M | 6.29M | 8.36M | 4.01M | 101.00K | 3.00K | 7.01M | 12.00K | 16.00K | 23.00K | 0.00 |
| Cost of Revenue | 3.46M | 33.34M | 49.41M | 36.89M | 2.26M | 2.84M | 2.13M | 30.54M | 22.00M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.05M | 28.46M | 36.35M | 27.47M | 4.03M | 5.52M | 1.88M | -30.44M | -22.00M | 5.96M | 12.00K | 16.00K | 23.00K | 0.00 |
| Gross Profit Ratio | 46.89% | 46.06% | 42.39% | 42.68% | 64.09% | 66.06% | 46.94% | -30,140.59% | -733,300.00% | 85.03% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 3.52M | 7.28M | 29.50M | 16.49M | 17.42M | 24.86M | 32.97M | 25.24M | 17.77M | 12.70M | 8.10M | 6.46M | 5.41M | 736.00K |
| General & Administrative | 28.88M | 54.97M | 76.60M | 25.38M | 11.48M | 7.51M | 8.03M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Selling & Marketing | 2.10M | 9.06M | 11.39M | 49.29M | 18.33M | 12.49M | 12.01M | 1.56M | 1.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.98M | 64.03M | 87.99M | 74.66M | 29.81M | 19.99M | 20.04M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Other Expenses | -44.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 845.00K | 0.00 | 100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -9.56M | 71.31M | 117.49M | 91.15M | 47.23M | 44.85M | 53.85M | 30.64M | 22.01M | 16.61M | 10.78M | 9.06M | 7.90M | 1.73M |
| Cost & Expenses | -6.10M | 104.64M | 166.89M | 128.04M | 49.49M | 47.69M | 55.98M | 30.64M | 22.01M | 17.66M | 10.78M | 9.06M | 7.90M | 1.73M |
| Interest Income | 93.76K | 140.00K | 51.00K | 270.00K | 1.34M | 678.00K | 6.51M | 1.55M | 1.12M | 319.00K | 158.00K | 119.00K | 14.00K | 2.00K |
| Interest Expense | 367.00K | 41.33M | 16.57M | 12.76M | 438.00K | 167.00K | 77.00K | 375.00K | 212.00K | 383.00K | 14.00K | 1.48M | 65.00K | 876.00K |
| Depreciation & Amortization | 1.99M | 8.12M | 18.16M | 8.81M | 1.22M | 89.71K | 81.57K | 44.14K | 36.00K | 27.00K | 24.00K | 24.00K | 15.00K | -63.00K |
| EBITDA | 26.31M | -42.84M | -63.03M | -54.94M | -40.78M | -38.60M | -45.79M | -30.50M | -21.87M | -10.62M | -10.75M | -9.02M | -7.86M | -2.55M |
| EBITDA Ratio | 403.94% | -56.00% | -73.46% | -84.94% | -646.21% | -461.28% | -1,132.67% | -28,664.36% | -694,733.33% | -146.86% | -88,250.00% | -56,837.50% | -36,456.52% | 0.00% |
| Operating Income | 12.63M | -42.84M | -81.14M | -63.68M | -43.20M | -39.33M | -51.97M | -30.54M | -22.00M | -10.65M | -10.77M | -9.04M | -7.87M | -1.73M |
| Operating Income Ratio | 193.95% | -69.33% | -94.61% | -98.95% | -686.71% | -470.47% | -1,297.03% | -30,240.59% | -733,400.00% | -151.80% | -89,766.67% | -56,500.00% | -34,230.43% | 0.00% |
| Total Other Income/Expenses | 11.32M | -28.83M | -16.61M | -12.49M | 897.00K | 511.00K | 6.43M | 1.17M | 812.00K | -64.00K | 144.00K | -1.29M | -7.63M | -811.00K |
| Income Before Tax | 23.95M | -71.67M | -97.74M | -76.17M | -42.30M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Income Before Tax Ratio | 367.75% | -115.97% | -113.98% | -118.36% | -672.45% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| Income Tax Expense | 0.00 | -12.42M | 16.57M | 12.84M | 1.33M | 727.00K | 6.29M | 1.27M | 900.00K | 222.00K | 142.00K | 1.29M | 7.63M | 874.00K |
| Net Income | 23.92M | -59.25M | -114.31M | -89.02M | -43.63M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Net Income Ratio | 367.19% | -95.87% | -133.30% | -138.31% | -693.59% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| EPS | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -94.96 | -76.13 | -49.47 | -68.15 | -80.00 | -128.96 | -19.35 |
| EPS Diluted | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -92.00 | -75.51 | -49.12 | -68.15 | -78.53 | -128.96 | -19.35 |
| Weighted Avg Shares Out | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 309.30K | 277.04K | 216.53K | 155.95K | 129.08K | 120.22K | 131.49K |
| Weighted Avg Shares Out (Dil) | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 319.24K | 279.29K | 218.06K | 155.95K | 131.49K | 120.22K | 131.49K |
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
Talicia® Launched in the United Arab Emirates
Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
Why Is RedHill Biopharma (RDHL) Stock Up 75% Today?
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
RedHill Biopharma Terminates License Agreement for Aemcolo®
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
Source: https://incomestatements.info
Category: Stock Reports